Working… Menu

Ziprasidone in Children With Autism: A Pilot Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00208559
Recruitment Status : Completed
First Posted : September 21, 2005
Last Update Posted : June 17, 2010
Information provided by:
Drexel University

Brief Summary:
The purpose of this study is to see if the drug, ziprasidone, is effective in treating problems in adolescent associated with autism.

Condition or disease Intervention/treatment Phase
Autism Drug: Ziprasidone Phase 2

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Ziprasidone in Children With Autism: A Pilot Study
Study Start Date : February 2002
Actual Primary Completion Date : June 2005
Actual Study Completion Date : August 2006

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
1 Open Label
Open Label
Drug: Ziprasidone
Ziprasidone 40mg to 60mg per day, individually titrated
Other Name: Geodon

Primary Outcome Measures :
  1. Clinical Global Impressions [ Time Frame: Week 6 ]

Secondary Outcome Measures :
  1. Children's Psychiatric Rating Scale [ Time Frame: Baseline, Week 6 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   12 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of autism (DSM-IV) made by a boarded child and adolescent psychiatrist.
  • Males and females.
  • Aged 12 to 18 years.
  • Clinical judgment that medication treatment for autism is indicated.

Exclusion Criteria:

  • Major medical problems including cardiac, liver, endocrine, or renal diseases.
  • History of seizure disorder or gross neurological deficit.
  • Baseline QTC greater than 425 msec.
  • Concomitant treatment with psychotropic medication.
  • History of prior exposure to ziprasidone.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00208559

Layout table for location information
United States, Pennsylvania
Drexel University College of Medicine at Friends Hospital
Philadelphia, Pennsylvania, United States, 19124
Sponsors and Collaborators
Drexel University College of Medicine
Layout table for investigator information
Principal Investigator: Richard P Malone, MD Drexel University College of Medicine

Layout table for additonal information
Responsible Party: Richard P. Malone, Drexel University College of Medicine Identifier: NCT00208559     History of Changes
Other Study ID Numbers: 00936
First Posted: September 21, 2005    Key Record Dates
Last Update Posted: June 17, 2010
Last Verified: June 2010
Keywords provided by Drexel University:
Pervasive Developmental Disorder
Additional relevant MeSH terms:
Layout table for MeSH terms
Autistic Disorder
Autism Spectrum Disorder
Child Development Disorders, Pervasive
Neurodevelopmental Disorders
Mental Disorders
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Dopamine Antagonists
Dopamine Agents